Who we are
NeoGenomics Laboratories is comprised of a national team of experts in developing and delivering laboratory diagnostic and clinical trial services with a focus in cancer. It is the common purpose of all NeoGenomics employees to save lives by improving patient CARE through Communication, Accuracy, Reliability, and Efficiency. Our staff physicians, scientists, laboratory professionals, client services representatives, and sales people team up with our clients. Together, we work to solve the medical, scientific, and logistical challenges of making precise diagnoses, aiding in bringing new therapies to market and finding the unique hallmarks of each patient’s disease that point the way to proper treatment.
What we do
We provide expert bone marrow and surgical pathology consults; cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor FISH testing with the largest menu of technical-only services available; 10-color flow cytometry; histology supported by an extensive IHC antibody library; and >160 molecular oncology tests comprising the most comprehensive combination of multi-method tumor profiles and targeted biomarker tests in the industry. Our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out FISH, flow cytometry, and/or IHC. Our Pharma Services division offers all of these methodologies along with other technology platforms to provide laboratory services that meet the rapidly evolving needs of our clients. Through our differentiators of expertise, flexibility and scalability we partner with our clients to develop better, more effective drugs.
We support clients in many cancer-related market segments including hospital and private pathology laboratories, office-based oncologists, academic institutions, contract research and pharmaceutical development organizations, and more.
Why it matters
People with cancer need more options, and we believe precision medicine is a critical component in controlling cancer. With all testing methodologies in one laboratory system, we have the ability to interrogate a blood-based cancer or solid tumor by as many means necessary to reveal biomarkers that expose that disease’s susceptibilities to standard or novel therapies. NeoGenomics’ extremely fast test development cycle means we are highly responsive to guideline changes and new therapy options. Design of our new tests always involves a balance of convention and innovation so costs are reduced and results become available promptly.
It all comes back to the patients. Time and results mean everything to our patients, and we keep that first in our minds.